319 related articles for article (PubMed ID: 32601232)
21. Residues W320 and Y328 within the binding site of the μ-opioid receptor influence opiate ligand bias.
Hothersall JD; Torella R; Humphreys S; Hooley M; Brown A; McMurray G; Nickolls SA
Neuropharmacology; 2017 May; 118():46-58. PubMed ID: 28283391
[TBL] [Abstract][Full Text] [Related]
22. Structure-Based Evolution of G Protein-Biased μ-Opioid Receptor Agonists.
Wang H; Hetzer F; Huang W; Qu Q; Meyerowitz J; Kaindl J; Hübner H; Skiniotis G; Kobilka BK; Gmeiner P
Angew Chem Int Ed Engl; 2022 Jun; 61(26):e202200269. PubMed ID: 35385593
[TBL] [Abstract][Full Text] [Related]
23. SR-17018 Stimulates Atypical µ-Opioid Receptor Phosphorylation and Dephosphorylation.
Fritzwanker S; Schulz S; Kliewer A
Molecules; 2021 Jul; 26(15):. PubMed ID: 34361663
[TBL] [Abstract][Full Text] [Related]
24. Agonist-directed interactions with specific beta-arrestins determine mu-opioid receptor trafficking, ubiquitination, and dephosphorylation.
Groer CE; Schmid CL; Jaeger AM; Bohn LM
J Biol Chem; 2011 Sep; 286(36):31731-41. PubMed ID: 21757712
[TBL] [Abstract][Full Text] [Related]
25. Molecular mechanisms of fentanyl mediated β-arrestin biased signaling.
de Waal PW; Shi J; You E; Wang X; Melcher K; Jiang Y; Xu HE; Dickson BM
PLoS Comput Biol; 2020 Apr; 16(4):e1007394. PubMed ID: 32275713
[TBL] [Abstract][Full Text] [Related]
26. Morphine induces μ opioid receptor endocytosis in guinea pig enteric neurons following prolonged receptor activation.
Patierno S; Anselmi L; Jaramillo I; Scott D; Garcia R; Sternini C
Gastroenterology; 2011 Feb; 140(2):618-26. PubMed ID: 21070774
[TBL] [Abstract][Full Text] [Related]
27. Critical Assessment of G Protein-Biased Agonism at the μ-Opioid Receptor.
Gillis A; Kliewer A; Kelly E; Henderson G; Christie MJ; Schulz S; Canals M
Trends Pharmacol Sci; 2020 Dec; 41(12):947-959. PubMed ID: 33097283
[TBL] [Abstract][Full Text] [Related]
28. Probing Allosteric Regulation Mechanism of W7.35 on Agonist-Induced Activity for μOR by Mutation Simulation.
Zhang F; Chen X; Chen J; Xu Y; Li S; Guo Y; Pu X
J Chem Inf Model; 2022 Nov; 62(21):5120-5135. PubMed ID: 34779608
[TBL] [Abstract][Full Text] [Related]
29. The G-protein-biased agents PZM21 and TRV130 are partial agonists of μ-opioid receptor-mediated signalling to ion channels.
Yudin Y; Rohacs T
Br J Pharmacol; 2019 Sep; 176(17):3110-3125. PubMed ID: 31074038
[TBL] [Abstract][Full Text] [Related]
30. Probing biased activation of mu-opioid receptor by the biased agonist PZM21 using all atom molecular dynamics simulation.
Liao S; Tan K; Floyd C; Bong D; Pino MJ; Wu C
Life Sci; 2021 Mar; 269():119026. PubMed ID: 33444617
[TBL] [Abstract][Full Text] [Related]
31. Receptor heterodimerization leads to a switch in signaling: beta-arrestin2-mediated ERK activation by mu-delta opioid receptor heterodimers.
Rozenfeld R; Devi LA
FASEB J; 2007 Aug; 21(10):2455-65. PubMed ID: 17384143
[TBL] [Abstract][Full Text] [Related]
32. Distinct domains of the mu-opioid receptor control uncoupling and internalization.
Celver J; Xu M; Jin W; Lowe J; Chavkin C
Mol Pharmacol; 2004 Mar; 65(3):528-37. PubMed ID: 14978231
[TBL] [Abstract][Full Text] [Related]
33. Comparison of [Dmt1]DALDA and DAMGO in binding and G protein activation at mu, delta, and kappa opioid receptors.
Zhao GM; Qian X; Schiller PW; Szeto HH
J Pharmacol Exp Ther; 2003 Dec; 307(3):947-54. PubMed ID: 14534366
[TBL] [Abstract][Full Text] [Related]
34. Agonist-selective mechanisms of mu-opioid receptor desensitization in human embryonic kidney 293 cells.
Johnson EA; Oldfield S; Braksator E; Gonzalez-Cuello A; Couch D; Hall KJ; Mundell SJ; Bailey CP; Kelly E; Henderson G
Mol Pharmacol; 2006 Aug; 70(2):676-85. PubMed ID: 16682505
[TBL] [Abstract][Full Text] [Related]
35. Molecular modeling of salsolinol, a full G
Berríos-Cárcamo P; Rivera-Meza M; Herrera-Marschitz M; Zapata-Torres G
Chem Biol Drug Des; 2019 Aug; 94(2):1467-1477. PubMed ID: 30920734
[TBL] [Abstract][Full Text] [Related]
36. A G protein-biased ligand at the μ-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine.
DeWire SM; Yamashita DS; Rominger DH; Liu G; Cowan CL; Graczyk TM; Chen XT; Pitis PM; Gotchev D; Yuan C; Koblish M; Lark MW; Violin JD
J Pharmacol Exp Ther; 2013 Mar; 344(3):708-17. PubMed ID: 23300227
[TBL] [Abstract][Full Text] [Related]
37. Novel Opioid Receptor Agonists with Reduced Morphine-like Side Effects.
Zhu L; Cui Z; Zhu Q; Zha X; Xu Y
Mini Rev Med Chem; 2018; 18(19):1603-1610. PubMed ID: 30009707
[TBL] [Abstract][Full Text] [Related]
38. Mu opioid receptor-effector coupling and trafficking in dorsal root ganglia neurons.
Walwyn WM; Wei W; Xie CW; Chiu K; Kieffer BL; Evans CJ; Maidment NT
Neuroscience; 2006 Oct; 142(2):493-503. PubMed ID: 16887280
[TBL] [Abstract][Full Text] [Related]
39. Biased Agonism of Endogenous Opioid Peptides at the μ-Opioid Receptor.
Thompson GL; Lane JR; Coudrat T; Sexton PM; Christopoulos A; Canals M
Mol Pharmacol; 2015 Aug; 88(2):335-46. PubMed ID: 26013541
[TBL] [Abstract][Full Text] [Related]
40. Opioid agonists differentially regulate mu-opioid receptors and trafficking proteins in vivo.
Patel MB; Patel CN; Rajashekara V; Yoburn BC
Mol Pharmacol; 2002 Dec; 62(6):1464-70. PubMed ID: 12435815
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
